AstraZeneca’s profit after tax rose 23% to $3.12 billion in the July-to-September period, while revenue increased 7% to $16.2 billion and core earnings per share rose 17% to $2.79. Oncology sales climbed 17% to $7.8 billion, led by Tagrisso and Imfinzi, offsetting pressure from generic competition affecting Farxiga, patent loss for Brilinta and China’s volume-based procurement system. The company launched its Reshaping for Sustainable Growth program, targeting $1.5 billion in annualized savings for reinvestment mainly in its drug-development pipeline. The plan could incur up to $2 billion in one-off restructuring charges, is expected to be largely complete by the end of 2029 and could involve job cuts, although none have been announced. AstraZeneca reaffirmed its 2026 outlook and remains on track for $80 billion in annual revenue by 2030. Shares rose more than 4.5% in early trading.